Defiance Autism Impact ETF
ASD - ETF AI Analysis
Top Page
Defiance Autism Impact ETF (ASD)
ASD, the Defiance Autism Impact ETF, appears to be a solid but not top-tier fund, supported by several strong healthcare and pharmaceutical holdings. High-quality names like Novartis, Otsuka Holdings, Roche, and Graham Holdings contribute positively through strong financial performance, robust pipelines, and generally favorable technical trends. The main risk factor is the fund’s concentration in drug and healthcare companies, where valuation concerns, leverage, and occasional bearish technical signals in holdings like Pearson and AbbVie can add volatility and limit the overall rating.
ASD vs. SPDR S&P 500 ETF (SPY)
- AUM
- 1.39M
- Region
- North America
- Expense Ratio
- 0.79%
- Beta
- 0.13
- Issuer
- Defiance
- Inception Date
- Jun 01, 2026
- Dividend Yield
- 0.03%
- Asset Class
- Equity
- Index Tracked
- VettaFi Autism Impact Index - USD - Benchmark TR Net
ASD Summary
The Defiance Autism Impact ETF (ASD) is a health care–focused fund that follows the VettaFi Autism Impact Index. It invests in companies that support people on the autism spectrum and the broader neurodiverse community, including firms working on treatments, diagnostics, telehealth, and assistive technologies. Well-known holdings include AbbVie and BioMarin Pharmaceutical. Investors might consider ASD if they want growth potential in health care while also supporting autism-related causes, since part of the profits go to autism organizations. A key risk is that it is heavily concentrated in the health care sector, so its price can rise or fall more than the overall stock market.
How much will it cost me?
This ETF has an expense ratio of 0.79%, which means you’ll pay about $7.90 per year for every $1,000 you invest. That’s higher than the average ETF because it’s a specialized, impact-focused fund that tracks a niche autism-related index rather than a broad, low-cost market index.
What would affect this ETF?
ASD could benefit if demand grows for autism-related health services, telehealth, and innovative treatments, especially as U.S. healthcare spending and support for neurodiversity and impact investing continue to rise, helping many of its specialized holdings. On the other hand, it could be hurt by changes in healthcare regulations or reimbursement, setbacks in drug development for companies like Eli Lilly, Jazz Pharmaceuticals, or Teva, or a broad downturn in the U.S. health care sector that would weigh on its concentrated portfolio.
ASD Top 10 Holdings
ASD leans heavily into health care, with a global tilt that mixes big U.S. names like Eli Lilly and AbbVie with Japanese pharma players such as Takeda and Otsuka. Recently, Otsuka and Revvity have been doing much of the heavy lifting, with rising momentum that helps set the tone for the fund. Teva and Medicover are also pulling their weight, adding steady support. On the flip side, Sumitomo Dainippon and Bright Horizons have been lagging, acting like a bit of sand in the fund’s gears despite the otherwise broad, neurodiversity-focused lineup.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 JP:4506 | Sumitomo Dainippon Pharma Co | 3.17% | $43.97K | JPY 869.60B | -8.01% | 66Neutral |
 RVTY | Revvity | 3.44% | $47.73K | $17.75B | 67.80% | 67Neutral |
 ACHC | Acadia Healthcare | 3.55% | $49.30K | $3.59B | 112.72% | 61Neutral |
 LLY | Eli Lilly & Co | 3.30% | $45.83K | $1.35T | 45.38% | 72Outperform |
 JP:4502 | Takeda Pharmaceutical Co | 2.99% | $41.55K | JPY 10.52T | 57.94% | 66Neutral |
 CH:NOVN | Novartis AG | 3.09% | $42.98K | CHF 246.17B | 27.54% | 80Outperform |
 BTSG | BrightSpring Health Services, Inc. | 3.28% | $45.52K | $14.42B | 114.16% | 67Neutral |
 RHHVF | Roche Holding AG | ― | ― | ― | ― | 73Outperform |
 GB:PSON | Pearson | 2.87% | $39.88K | GBP 7.72B | 27.93% | 73Outperform |
 IL:TEVA | Teva | 3.04% | $42.22K | ILS 157.40B | 68.60% | 61Neutral |
ASD Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For ASD, the sentiment is Positive. The current price of 27.86 is above the 20-day moving average (MA) of 27.34, above the 50-day MA of 27.12, and compared to the 200-day MA of , indicating a neutral trend. The MACD of 0.21 indicates Negative momentum. The RSI at 60.70 is Neutral, neither overbought nor oversold. The STOCH value of 100.24 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ASD.
ASD Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| ASD | $27.86 | $29.00(4.10% Upside) | $1.39M | 0.79% | 62Neutral |
 RIET | $8.16 | $9.62(17.94% Upside) | $97.81M | 0.50% | 55Neutral |
 GXPC | $27.47 | $36.77(33.84% Upside) | $97.04M | 0.15% | 78Outperform |
 RSPR | $36.04 | $40.07(11.18% Upside) | $88.42M | 0.40% | 67Neutral |
 BBC | $45.21 | $103.40(128.73% Upside) | $31.26M | 0.65% | 43Neutral |
 TRUH | $32.97 | $35.00(6.16% Upside) | $607.73K | 0.10% | 73Outperform |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ASD | Defiance Autism Impact ETF | 27.86 | 3.00 | 12.05% | |
| RIET | Hoya Capital High Dividend Yield ETF | 8.16 | -0.19 | -2.29% | |
| GXPC | Global X PureCap MSCI Communication Services ETF | 27.47 | -0.27 | -0.97% | |
| RSPR | Invesco S&P 500 Equal Weight Real Estate ETF | 36.04 | 3.41 | 10.43% | |
| BBC | Virtus LifeSci Biotech Clinical Trials ETF | 45.21 | 14.27 | 46.11% | |
| TRUH | VanEck Healthcare TruSector ETF | 32.97 | 7.57 | 29.80% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.